Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma

Journal of Medicinal Chemistry

Volumn 58, Issue 16, 2015, Pages 6507-6515

  Iakovleva, Irina ^a   Brännström, Kristoffer ^a   Nilsson, Lina ^a   Gharibyan, Anna L ^a   Begum, Afshan ^a   Anan, Intissar ^a   Walfridsson, Malin ^a   Sauer Eriksson, A Elisabeth ^a   Olofsson, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; APIGENIN; DICLOFENAC; DIFLUNISAL; GEMFIBROZIL; LIGAND; LUTEOLIN; MECLOFENAMIC ACID; NIFLUMIC ACID; PLASMA PROTEIN TRANSTHYRETIN; PREALBUMIN; TOLFENAMIC ACID; UNCLASSIFIED DRUG; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; ENTHALPY; HUMAN; HYDROGEN BOND; IC50; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MOLECULAR WEIGHT; PLASMA; PROTEIN EXPRESSION; PROTEIN PURIFICATION; AMYLOIDOSIS; CALORIMETRY; CHEMICAL STRUCTURE; CHEMISTRY; THERMODYNAMICS; X RAY DIFFRACTION;

AMYLOIDOSIS; CALORIMETRY; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; PLASMA; PREALBUMIN; PROTEIN BINDING; THERMODYNAMICS; X-RAY DIFFRACTION;

EID: 84940506671     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00544     Document Type: Article

References (52)

1. Westermark, P.; Sletten, K.; Johansson, B.; Cornwell, G. G., 3rd Fibril in senile systemic amyloidosis is derived from normal transthyretin Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 2843-2845 10.1073/pnas.87.7.2843
2. Saraiva, M. J.; Magalhaes, J.; Ferreira, N.; Almeida, M. R. Transthyretin deposition in familial amyloidotic polyneuropathy Curr. Med. Chem. 2012, 19, 2304-2311 10.2174/092986712800269236
3. Ruberg, F. L.; Berk, J. L. Transthyretin (TTR) cardiac amyloidosis Circulation 2012, 126, 1286-1300 10.1161/CIRCULATIONAHA.111.078915
4. Benson, M. D. Leptomeningeal amyloid and variant transthyretins Am. J. Pathol. 1996, 148, 351-354
5. Kalkunte, S. S.; Neubeck, S.; Norris, W. E.; Cheng, S. B.; Kostadinov, S. et al. Transthyretin is dysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model Am. J. Pathol. 2013, 183, 1425-1436 10.1016/j.ajpath.2013.07.022
6. Westermark, P.; Westermark, G. T.; Suhr, O. B.; Berg, S. Transthyretin-derived amyloidosis: Probably a common cause of lumbar spinal stenosis Upsala J. Med. Sci. 2014, 119, 223-228 10.3109/03009734.2014.895786
7. Quintas, A.; Vaz, D. C.; Cardoso, I.; Saraiva, M. J.; Brito, R. M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants J. Biol. Chem. 2001, 276, 27207-27213 10.1074/jbc.M101024200
8. Cardoso, I.; Goldsbury, C. S.; Muller, S. A.; Olivieri, V.; Wirtz, S. et al. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils J. Mol. Biol. 2002, 317, 683-695 10.1006/jmbi.2002.5441
9. Redondo, C.; Damas, A. M.; Saraiva, M. J. Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity Biochem. J. 2000, 348 (Part 1) 167-172 10.1042/0264-6021:3480167
10. Kelly, J. W.; Colon, W.; Lai, Z.; Lashuel, H. A.; McCulloch, J. et al. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid Adv. Protein Chem. 1997, 50, 161-181 10.1016/S0065-3233(08)60321-6
11. Vaidya, B.; Pearce, S. H. S. Diagnosis and management of thyrotoxicosis BMJ 2014, 349 10.1136/bmj.g5128
12. Klabunde, T.; Petrassi, H. M.; Oza, V. B.; Raman, P.; Kelly, J. W.; Sacchettini, J. C. et al. Rational design of potent human transthyretin amyloid disease inhibitors Nat. Struct. Mol. Biol. 2000, 7, 312-321 10.1038/74082
13. Miller, S. R.; Sekijima, Y.; Kelly, J. W. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants Lab. Invest. 2004, 84, 545-552 10.1038/labinvest.3700059
14. Tojo, K.; Sekijima, Y.; Kelly, J. W.; Ikeda, S. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis Neurosci. Res. 2006, 56, 441-449 10.1016/j.neures.2006.08.014
15. Mairal, T.; Nieto, J.; Pinto, M.; Almeida, M. R.; Gales, L. et al. Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors PLoS One 2009, 4, e4124 10.1371/journal.pone.0004124
16. Ferreira, N.; Saraiva, M. J.; Almeida, M. R. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation FEBS Lett. 2011, 585, 2424-2430 10.1016/j.febslet.2011.06.030
17. Ferreira, N.; Saraiva, M. J.; Almeida, M. R. Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy Amyloid 2012, 19 (Suppl. 1) 39-42 10.3109/13506129.2012.668502
18. Ferreira, N.; Santos, S. A.; Domingues, M. R.; Saraiva, M. J.; Almeida, M. R. Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition Biochim. Biophys. Acta, Mol. Basis Dis. 2013, 1832, 39-45 10.1016/j.bbadis.2012.10.007
19. Sant'Anna, R. O.; Braga, C. A.; Polikarpov, I.; Ventura, S.; Lima, L. M. T. R.; Foguel, D. et al. Inhibition of Human Transthyretin Aggregation by Non-Steroidal Anti-Inflammatory Compounds: A Structural and Thermodynamic Analysis Int. J. Mol. Sci. 2013, 14, 5284-5311 10.3390/ijms14035284
20. Cotrina, E. Y.; Pinto, M.; Bosch, L.; Vila, M.; Blasi, D. et al. Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation J. Med. Chem. 2013, 56, 9110-9121 10.1021/jm401061w
21. Vilaro, M.; Nieto, J.; La Parra, J. R.; Almeida, M. R.; Ballesteros, A. et al. Tuning transthyretin amyloidosis inhibition properties of iododiflunisal by combinatorial engineering of the nonsalicylic ring substitutions ACS Comb. Sci. 2015, 17, 32-38 10.1021/co5001234
22. Sant'anna, R. O.; Braga, C. A.; Polikarpov, I.; Ventura, S.; Lima, L. M. et al. Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysis Int. J. Mol. Sci. 2013, 14, 5284-5311 10.3390/ijms14035284
23. Trivella, D. B.; dos Reis, C. V.; Lima, L. M.; Foguel, D.; Polikarpov, I. Flavonoid interactions with human transthyretin: combined structural and thermodynamic analysis J. Struct. Biol. 2012, 180, 143-153 10.1016/j.jsb.2012.07.008
24. Trivella, D. B.; Sairre, M. I.; Foguel, D.; Lima, L. M.; Polikarpov, I. The binding of synthetic triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative and non-cooperative ligand recognition J. Struct. Biol. 2011, 173, 323-332 10.1016/j.jsb.2010.10.003
25. Alhamadsheh, M. M.; Connelly, S.; Cho, A.; Reixach, N.; Powers, E. T. et al. Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity Sci. Transl. Med. 2011, 3, 97ra81 10.1126/scitranslmed.3002473
26. Penchala, S. C.; Connelly, S.; Wang, Y.; Park, M. S.; Zhao, L. et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 9992-9997 10.1073/pnas.1300761110
27. Berk, J. L.; Suhr, O. B.; Obici, L.; Sekijima, Y.; Zeldenrust, S. R. et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial JAMA 2013, 310, 2658-2667 10.1001/jama.2013.283815
28. Coelho, T.; Maia, L. F.; Martins da Silva, A.; Waddington Cruz, M.; Plante-Bordeneuve, V. et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial Neurology 2012, 79, 785-792 10.1212/WNL.0b013e3182661eb1
29. Rappley, I.; Monteiro, C.; Novais, M.; Baranczak, A.; Solis, G. et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange Biochemistry 2014, 53, 1993-2006 10.1021/bi500171j
30. Nencetti, S.; Rossello, A.; Orlandini, E. Tafamidis (Vyndaqel): A Light for FAP Patients ChemMedChem 2013, 8, 1617-1619 10.1002/cmdc.201300245
31. Munro, S. L.; Lim, C. F.; Hall, J. G.; Barlow, J. W.; Craik, D. J. et al. Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin J. Clin. Endocrinol. Metab. 1989, 68, 1141-1147 10.1210/jcem-68-6-1141
32. Baures, P. W.; Oza, V. B.; Peterson, S. A.; Kelly, J. W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid Bioorg. Med. Chem. 1999, 7, 1339-1347 10.1016/S0968-0896(99)00066-8
33. Maetzler, W.; Tian, Y.; Baur, S. M.; Gauger, T.; Odoj, B. et al. Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia PLoS One 2012, 7, e48042 10.1371/journal.pone.0048042
34. Sekijima, Y.; Dendle, M. A.; Kelly, J. W. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis Amyloid 2006, 13, 236-249 10.1080/13506120600960882
35. Iakovleva, I.; Begum, A.; Pokrzywa, M.; Walfridsson, M.; Sauer-Eriksson, A. E. et al. The flavonoid luteolin, but not luteolin-7-o-glucoside, prevents a transthyretin mediated toxic response PLoS One 2015, 10, e0128222 10.1371/journal.pone.0128222
36. Hongo, M.; Kono, J.; Yamada, H.; Misawa, T.; Tanaka, M. et al. Doppler echocardiographic assessments of left ventricular diastolic filling in patients with amyloid heart disease J. Cardiol. 1991, 21, 391-401
37. Sousa, M. M.; Cardoso, I.; Fernandes, R.; Guimaraes, A.; Saraiva, M. J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates Am. J. Pathol. 2001, 159, 1993-2000 10.1016/S0002-9440(10)63050-7
38. Reixach, N.; Deechongkit, S.; Jiang, X.; Kelly, J. W.; Buxbaum, J. N. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 2817-2822 10.1073/pnas.0400062101
39. Lindhagen-Persson, M.; Vestling, M.; Reixach, N.; Olofsson, A. Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form Amyloid 2008, 15, 240-245 10.1080/13506120802524916
40. Reixach, N.; Adamski-Werner, S. L.; Kelly, J. W.; Koziol, J.; Buxbaum, J. N. Cell based screening of inhibitors of transthyretin aggregation Biochem. Biophys. Res. Commun. 2006, 348, 889-897 10.1016/j.bbrc.2006.07.109
41. Ferguson, R. N.; Edelhoch, H.; Saroff, H. A.; Robbins, J.; Cahnmann, H. J. Negative cooperativity in the binding of thyroxine to human serum prealbumin. Preparation of tritium-labeled 8-anilino-1-naphthalenesulfonic acid Biochemistry 1975, 14, 282-289 10.1021/bi00673a014
42. Cheng, S. Y.; Pages, R. A.; Saroff, H. A.; Edelhoch, H.; Robbins, J. Analysis of thyroid hormone binding to human serum prealbumin by 8-anilinonaphthalene-1-sulfonate fluorescence Biochemistry 1977, 16, 3707-3713 10.1021/bi00635a031
43. Kawasaki, Y.; Freire, E. Finding a better path to drug selectivity Drug Discovery Today 2011, 16, 985-990 10.1016/j.drudis.2011.07.010
44. Cheng, T.; Zhao, Y.; Li, X.; Lin, F.; Xu, Y. et al. Computation of octanol-water partition coefficients by guiding an additive model with knowledge J. Chem. Inf. Model. 2007, 47, 2140-2148 10.1021/ci700257y
45. Lu, X.; Sun, D.; Chen, Z.; Ye, J.; Wang, R. et al. Evaluation of hepatic clearance and drug-drug interactions of luteolin and apigenin by using primary cultured rat hepatocytes Pharmazie 2011, 65, 600-605
46. Vessby, B.; Lithell, H.; Boberg, J.; Hellsing, K.; Werner, I. Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial Proc. R Soc. Med. 1976, 69 (Suppl. 2) 32-37
47. Bulawa, C. E.; Connelly, S.; Devit, M.; Wang, L.; Weigel, C. et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 9629-9634 10.1073/pnas.1121005109
48. Johnson, S. M.; Connelly, S.; Wilson, I. A.; Kelly, J. W. Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies J. Med. Chem. 2009, 52, 1115-1125 10.1021/jm801347s
49. Hornberg, A.; Eneqvist, T.; Olofsson, A.; Lundgren, E.; Sauer-Eriksson, A. E. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin J. Mol. Biol. 2000, 302, 649-669 10.1006/jmbi.2000.4078
50. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement J. Appl. Crystallogr. 1997, 30, 1022-1025 10.1107/S0021889897006766
51. Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 213-221 10.1107/S0907444909052925
52. McNicholas, S.; Potterton, E.; Wilson, K. S.; Noble, M. E. Presenting your structures: the CCP4mg molecular-graphics software Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 386-394 10.1107/S0907444911007281